JNJ
嬌生 JOHNSON & JOHNSON
+1.48 (+0.55%)268.76USD1.9M成交股數648B市值31.2本益比(近四季)6.6股價營收比+6.6%營收年增(近四季)2026-10-13下次財報
財報 SEC XBRL 申報值 · 美元 · 財年於 1 月結束
逐季數字是 10-Q 的單季值;財年第四季 XBRL 只有年度值,這裡用年度減前三季推算。年增率比的是去年同一會計季。
營收與利潤率近 16 季
稀釋 EPS近 16 季 · 美元
現金流近 16 季
股東回饋近 16 季 · 庫藏股與股利
損益表 逐季 · 最新在左 · 小字是年增率
| 科目 | 27Q2 | 27Q1 | 26Q4 | 26Q3 | 26Q2 | 26Q1 | 25Q3 | 25Q2 | 25Q1 | 24Q4 | 24Q3 | 24Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營收 | 25.3B+7% | 24.1B+10% | 24.6B+9% | 24.0B+7% | 23.7B+11% | 21.9B+2% | 22.5B+5% | 22.4B+4% | 21.4B | 21.4B | 21.4B | 21.5B |
| 營業成本 | 8.1B | 8.1B | 8.0B | 7.3B | 7.6B | 7.4B | 7.0B | 6.9B | 6.5B | – | 6.6B | 6.5B |
| 毛利 | 17.3B+7% | 16.0B+10% | 16.6B+7% | 16.7B+7% | 16.1B+8% | 14.5B-0% | 15.5B+5% | 15.6B+3% | 14.9B | 14.6B | 14.7B | 15.1B |
| 毛利率 | 68.2% | 66.3% | 67.6% | 69.6% | 67.9% | 66.4% | 69.0% | 69.4% | 69.6% | 68.2% | 69.1% | 70.0% |
| 研發費用 | 3.7B | 3.5B | −10.3B | 3.7B | 3.5B | 3.2B | 5.0B | 3.4B | 3.5B | – | 3.4B | 3.7B |
| 銷售管理費用 | 6.4B | 6.0B | 6.8B | 5.9B | 5.9B | 5.1B | 5.5B | 5.7B | 5.3B | – | 5.4B | 5.4B |
| 營業利益 | – | – | – | – | – | – | – | – | – | – | – | – |
| 營業利益率 | – | – | – | – | – | – | – | – | – | – | – | – |
| 稅後淨利 | 5.5B-0% | 5.2B-52% | 5.1B+90% | 5.2B+10% | 5.5B+70% | 11.0B+172% | 2.7B-90% | 4.7B-9% | 3.3B | 4.0B | 26.0B | 5.1B |
| 淨利率 | 21.9% | 21.8% | 20.8% | 21.5% | 23.3% | 50.2% | 12.0% | 20.9% | 15.2% | 18.9% | 121.9% | 23.9% |
| 稀釋 EPS | 2.27-1% | 2.14-53% | 2.08+87% | 2.12+10% | 2.29+71% | 4.54+172% | 1.11-89% | 1.93-2% | 1.34 | 1.67 | 10.21 | 1.96 |
| 稀釋股數 | 2.44B | 2.45B | 2.43B | 2.43B | 2.42B | 2.42B | 2.43B | 2.42B | 2.43B | – | 2.55B | 2.63B |
資產負債表 期末餘額
| 科目 | 27Q2 | 27Q1 | 26Q4 | 26Q3 | 26Q2 | 26Q1 | 25Q3 | 25Q2 | 25Q1 | 24Q4 | 24Q3 | 24Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 現金與約當現金 | 20.4B | 21.7B | 19.7B | 18.2B | 18.6B | 38.5B | 20.0B | 24.9B | 25.5B | 21.9B | 19.7B | 21.2B |
| 應收帳款 | 19.0B | 17.7B | 17.2B | 17.6B | 17.8B | 16.0B | 16.2B | 15.8B | 14.9B | 14.9B | 14.8B | 16.8B |
| 存貨 | 15.1B | 14.6B | 14.2B | 14.1B | 13.4B | 12.7B | 12.6B | 12.2B | 11.4B | 11.2B | 11.2B | 12.9B |
| 總資產 | 201B | 201B | 199B | 193B | 193B | 194B | 178B | 181B | 172B | 168B | 166B | 192B |
| 有息負債 | 37.3B | 37.5B | 39.4B | 39.4B | 39.2B | 38.4B | 31.3B | 31.6B | 25.1B | 25.9B | 26.1B | 33.9B |
| 總負債 | 116B | 120B | 118B | 114B | 115B | 116B | 108B | 110B | 102B | 98.8B | 94.8B | 115B |
| 股東權益 | 85.0B | 81.2B | 81.5B | 79.3B | 78.5B | 78.1B | 70.2B | 71.5B | 70.0B | 68.8B | 71.2B | 75.1B |
| 負債比 | 57.7% | 59.6% | 59.1% | 58.9% | 59.4% | 59.7% | 60.6% | 60.5% | 59.3% | 59.0% | 57.1% | 60.1% |
| 淨現金(現金 − 有息負債) | −16.9B | −15.8B | −19.7B | −21.2B | −20.7B | 119M | −11.3B | −6.8B | 391M | −4.0B | −6.3B | −12.7B |
現金流量表 單季
| 科目 | 27Q2 | 27Q1 | 26Q4 | 26Q3 | 26Q2 | 26Q1 | 25Q3 | 25Q2 | 25Q1 | 24Q4 | 24Q3 | 24Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營業現金流 | – | 2.5B-40% | – | – | – | 4.2B | – | – | 3.7B | – | – | – |
| 資本支出 | – | 1.0B | – | – | – | 795M | – | – | 807M | – | – | – |
| 自由現金流 | – | 1.5B-57% | – | – | – | 3.4B | – | – | 2.9B | – | – | – |
| 折舊攤銷 | – | 2.0B | – | – | – | 1.8B | – | – | 1.8B | – | – | – |
| 買回庫藏股 | – | 4.0B | – | – | – | 2.1B | – | – | 1.5B | – | – | – |
| 現金股利 | – | – | – | – | – | – | – | – | – | – | – | – |
| 自由現金流率 | – | 6.1% | – | – | – | 15.4% | – | – | 13.3% | – | – | – |
營收拆解 2025 年度 10-K 的分部揭露 · 年增對前一年度
業務分部2025 年度 · 94.2B
| Innovative Medicine | 60.4B | 64.1% | +6.0% |
|---|---|---|---|
| Med Tech | 33.8B | 35.9% | +6.1% |
地區2025 年度 · 40.4B
| 歐洲 | 21.5B | 53.3% | +6.5% |
|---|---|---|---|
| Asia Pacific Africa | 14.0B | 34.7% | +3.2% |
| Western Hemisphere Excluding US | 4.9B | 12.1% | +3.4% |
| 美國 小計 | 53.8B | 132.9% | +6.9% |
| 美國以外 小計 | 40.4B | 100.0% | +5.0% |
各維度的加總不一定等於合併營收:分部有時含內部交易、地區有時只揭露主要國家。挑的是加總最接近合併營收的那個標籤。
年度 10-K
| 財年 | 營收 | 年增 | 稅後淨利 | 淨利率 | 稀釋 EPS | 自由現金流 |
|---|---|---|---|---|---|---|
| FY2026 | 94.2B | +6.0% | 26.8B | 28.5% | 11.03 | 19.7B |
| FY2025 | 88.8B | +4.3% | 14.1B | 15.8% | 5.79 | 19.8B |
| FY2024 | 85.2B | +6.5% | 35.2B | 41.3% | 13.72 | 18.2B |
| FY2023 | 80.0B | +1.6% | 17.9B | 22.4% | 6.73 | 17.2B |
| FY2022 | 78.7B | -4.7% | 20.9B | 26.5% | 7.81 | 19.8B |
| FY2021 | 82.6B | +0.6% | 14.7B | 17.8% | 5.51 | 20.2B |
| FY2020 | 82.1B | +0.6% | 15.1B | 18.4% | 5.63 | 19.9B |
| FY2019 | 81.6B | – | 15.3B | 18.8% | 5.61 | 18.5B |